Meeting
2016 Genitourinary Cancers Symposium
Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
Authors
Joseph Clark
Loyola University Medical Center, Maywood, IL
Joseph Clark , Michael A. Morse , Michael K.K. Wong , David F. McDermott , Howard Kaufman , Gregory A. Daniels , Jessica C Perritt , Hong Hua , Sandra Aung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01415167
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 511)
DOI
10.1200/jco.2016.34.2_suppl.511
Abstract #
511
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.
First Author: Joseph Clark
Poster
2015 Genitourinary Cancers Symposium
High-dose interleukin-2 (HD IL-2) for metastatic renal CELL carcinoma (mRCC): Contemporary utilization trends in the United States.
First Author: Christopher B. Allard
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).
First Author: Martin H Voss
Poster
2020 Genitourinary Cancers Symposium
Treatment-free survival after discontinuation of immuno-checkpoint therapy, and outcome of subsequent molecular targeted therapy: Retrospective study of Japanese metastatic renal cell carcinoma patients (after I-O study).
First Author: Yoshihiko Tomita